Discusses the role of vascular endothelial growth factor receptor 3 (VEGFR-3) inhibitors as anti-cancer agents. Suggestion that systemic administration of the VEGRF-3 antibody may reduce tumor-associated lymphangiogenesis and cancer metastasis without affecting physiologic lymphatic flow; Function of VEGFR-3 in pre-existing lymphatic vessels and angiogenesis.